The Psychedelic Center for Wellbeing

PROJECT DESCRIPTION

Open Mind Collective will build The Psychedelic Center for Wellbeing and an associated Psychedelic Mental Health Network across San Francisco, connecting mental health clinics and community partners to provide equitable care, advance research, and teach clinical skills utilizing psychedelic medicines.

Double-exposure profile of a person blended with dramatic sunlit clouds

MISSION STATEMENT

Creating New Pathways for Healing

Our mission is to conduct research, teach, and provide direct care using psychedelic medicine and other means to heal the minds and hearts of traumatized and vulnerable individuals and communities, alleviating transgenerational suffering.

GENERAL STRUCTURE

The Psychedelic Mental Health Network

Open Mind Collective logo

Coordinating backbone and clinical/community network

California Institute of Integral Studies logo

Phase 4 data collection/research + workforce development and scalable care models

University of California San Francisco logo
Zuckerberg San Francisco General Hospital & Trauma Center logo

Safety-net implementation and Medi-Cal evidence

UC Berkeley Center for the Science of Psychedelics logo

Public education and harm reduction

EXECUTIVE SUMMARY

Scaling Psychedelic Care Responsibly

A critical moment for equitable access to psychedelic care in San Francisco.

San Francisco faces an urgent mental health crisis: persistent depression, trauma, addiction, and overdose, alongside a care system that often fails those struggling with severe, recurrent, or treatment-resistant illness. At this same time, psychedelic medicines are imminently moving from clinical research toward legal, regulated care. Without deliberate effort, they will arrive through fragmented, high-cost commercial models that most San Franciscans in need cannot reach.

A network to integrate psychedelic therapies into the mental healthcare system.

Open Mind Collective will build the public-interest infrastructure integrating psychedelic therapies responsibly into San Francisco’s mental-healthcare system. Using a hub-and-spoke model, the OMC Psychedelic Center for Wellbeing will serve as the clinical, research, training, and evaluation hub for a network of community mental-health providers, academic institutions, training programs, and public-sector partners.

Together, the network will translate emerging evidence into safe, ethical, measurable, and accessible care. We will pilot group and community-based models that lower the cost of treatment, train a diverse workforce, set shared standards for quality and safety, and bring these emerging treatments where San Franciscans already receive services.

Coordination with vulnerable communities to design an equitable care program.

Communities disproportionately affected by trauma, depression, and barriers to care, including people living with addiction, first responders, and LGBTQ+ San Franciscans, will help co-design programs and measures of success. Beginning with Medi-Cal pilots and insurance-based clinical settings, we will build reimbursement pathways so that care continues after grant funding ends.

A national model for responsible psychedelic treatments.

Our goal is to actualize a new mental-healthcare ecosystem that enables San Francisco to become a national model for psychedelic treatments moving responsibly from research to practice as durable, equitable systemic change to mental healthcare.

KEY PARTNERSHIPS

Partners Across Research, Care, and Education

California Institute of Integral Studies logo

The California Institute of Integral Studies partnership is stewarded by Dr. Janis Phelps. CIIS has six community-based mental health clinics in San Francisco, serving 2,000 people per year with low-fee psychotherapy since 1983…

READ MORE

At the heart of its clinical services is a commitment to building equity in health care access by mitigating against the impact of systemic inequities by how they provide services and training in San Francisco.

In 2014, they founded the first ever university approved, post-graduate certificate program in Psychedelic-Assisted Therapy and Research, training 1,900 US and international medical and mental health professionals so far.

Three core members of the proposal’s partners are CIIS certificate graduates. Four experts in these partnerships have been mentors and teachers in the certificate program. These experts form an integrated team with common foundations of consensus on best practices for psychedelic-assisted psychotherapy, clinical psychedelic research, and public education needed for San Franciscans.

University of California San Francisco logo
Zuckerberg San Francisco General Hospital & Trauma Center logo

The UCSF/ZSFG partnership is stewarded by Nicky Mehtani, MD, MPH and Brian Anderson, MD, two physician-researchers dedicated to bringing psychedelic treatments to San Franciscans in greatest need…

READ MORE

These UCSF investigators already conduct psychedelic trials in publicly insured populations and bring established relationships across ZSFG and SFDPH. In connection with SFDPH Behavioral Health Services, they can ensure that psychedelic innovation reaches San Franciscans served by Medi-Cal.

The partnership builds on an existing collaboration between OMC and UCSF investigators with complementary strengths: OMC will develop the citywide clinical workforce, community, and implementation network, while UCSF/ZSFG will lead pragmatic implementation focused on people with non-psychotic mental illness and substance use disorders who are already receiving care through San Francisco’s safety net.

These studies will test models embedded in existing care settings, including Medi-Cal-funded residential addiction treatment programs to create effective implementation while generating cost data needed for payer adoption.

UC Berkeley Center for the Science of Psychedelics logo

Together with diverse peoples and organizations, the BCSP created a co-design process for a national psychedelics public education campaign…

READ MORE

Together with diverse peoples and organizations, the BCSP created a co-design process for a national psychedelics public education campaign. These partners bring expertise and lived experience in plant medicines, knowledge-holding, risk reduction, and psychedelics education.

In direct partnership with OMC, this public health education campaign will be tailored specifically for San Franciscans with a focus intended to maximize benefits and reduce risks of psychedelic use. There is not a clear source for public education about psychedelics in California and because legal avenues for psychedelic use are shifting, we anticipate increases in use for most demographics across San Francisco and the Bay Area.

The public needs sound, credible, accessible, non-stigmatizing, compassionate, and culturally relevant information about psychedelics to support informed decision-making before, during, and after psychedelic use. The Psychedelic Center for Wellbeing will host educational events to support public education and clinical education through its Psychedelic Mental Health Network.

KEY LEADERSHIP

Expertise Built Across the Full Continuum of Care

Our leadership team and associated partners have devoted decades to caring for people with depression, PTSD, anxiety, addiction, and other difficult-to-treat psychiatric conditions across academic, public-sector, private-practice, military, and community settings.

From Research to Real-World Care

With UCSF and UC Berkeley affiliations, our team brings direct experience conducting FDA-regulated clinical trials of investigational psychedelic medicines, including MDMA-assisted therapy for PTSD, 5-MeO-DMT-assisted therapy for depression, ketamine- and psilocybin-assisted therapies for substance use, depression, and anxiety disorders, and psychedelic studies specifically designed to reach publicly-insured San Franciscans. This experiential knowledge provides expertise in translating emerging psychedelic science into clinical care and navigating regulatory, operational, safety, and equity considerations in underserved populations.

Translating Evidence Into Practice

Beyond conducting research, our clinicians have built programs across academic, public-sector, and community-based settings, with robust existing relationships spanning mental health treatment facilities, first responders, local nonprofits, and clinical training institutions. Our group’s own insurance-based ketamine practice provides operational proof of the proposed model, with real-world experience integrating psychedelic-informed treatment into a reimbursable clinical model. In partnership with CIIS, we have capacity to provide targeted clinical training to multidisciplinary clinicians through the proposed Psychedelic Mental Health Network and can develop and implement novel group psychedelic treatment models.

Expanding Access, Elevating Standards

Our strength is bridging worlds that too often operate separately: rigorous science and compassionate care; academic research and community practice; innovation and safety. We aim to build a San Francisco institution that delivers psychedelic treatments and sets standards of care for the field: developing, evaluating, and teaching new models of mental healthcare that most San Franciscans could not otherwise access.

Dr Sylvestre Quevedo

Sylver Quevedo MD MPH

Board Chair & Co-Founder, Open Mind Collective

Physician-executive, academic leader, and clinical investigator with decades of experience spanning medicine, public health, health-system innovation, and psychedelic research.Physician-executive, academic leader, and clinical investigator with decades of experience spanning medicine, public health, health-system innovation, and psychedelic research.

READ MORE

A Harvard-trained internal medicine physician and public-health specialist, he has held senior leadership roles at Stanford, UCSF, and Duke. He helped found UCSF’s Osher Center for Integrative Medicine, establishing a major San Francisco-based center for innovative, interdisciplinary care.

Dr. Quevedo served as Principal Investigator for MDMA-assisted psychotherapy for PTSD and 5-MeO-DMT-assisted therapy for depression, bringing exceptional leadership across clinical research, systems design, and implementation.

Sidney Edsall, MD

Sidney Edsall MD

Vice Chair & Co-Founder, Open Mind Collective

Dr. Edsall completed her psychiatry residency at Stanford in 2006 and has since worked in academic, community-based, and active-duty military healthcare settings. She is the founder of Quantum Integral Healing Arts, a multidisciplinary integrative mental health clinic and co-founder of the nonprofit Open Mind Collective.

READ MORE

Her research spans multiple psychedelic research trials, to include MDMA-assisted therapy for PTSD, 5-MeO-DMT for depression, and she is currently the principal investigator for 2 novel psilocybin-like medications for depression and generalized anxiety disorder.

In her clinic, she teaches and utilizes ketamine assisted psychotherapy and incorporates mindfulness, meditation, and acupuncture in her treatment protocols.

Dr Sylvestre Quevedo

Charlie Bathgate aMFT

Chief Operating Officer, Open Mind Collective

Charlie Bathgate is an Associate Marriage and Family Therapist and company founder with over 15 years of operational, leadership, and financial experience currently serving as Treasurer of Open Mind Collective (a 501c3) and Chief Operating Officer of Open Mind Therapeutics.

READ MORE

He provides ketamine-assisted and conventional therapy at Quantum Integral Healing Arts and serves as a session monitor for Open Mind Therapeutics clinical trials, including Helus Pharma’s CYB-003 (a psilocin-based molecule) and Reunion Neuroscience’s RE104 (a 4-OH-DiPT prodrug).

He has completed multiple psychedelic-assisted therapy training programs and served as Board Member and Interim Board Chair of Alchemy Community Therapy Center in Oakland, CA. He has also held leadership roles at several financial technology companies, most recently as CEO of Fuzion Trading and Fuzion Analytics, which provide education and technology to US equity, equity options, and futures traders. He has helped raise over $50M across his organizations.

He earned his Master’s in Counseling Psychology from The Wright Institute in 2023 and his undergraduate degree from Duke University in 2009.

Sidney Edsall, MD

Kaila Compton MD PhD

Director of Clinical Services, Open Mind Collective • Lead Physician of Interventional Psychiatry+Attending Physician, Bay Area Psychiatric Association (Berkeley)

Dr. Kaila Compton is a psychiatrist and Medical Director of the proposed Psychedelic Center of Excellence. She earned a PhD in Social Anthropology from Harvard University and completed medical school through the UC Berkeley–UCSF Joint Medical Program and psychiatry residency at UCSF.

READ MORE

She has worked in psychedelic medicine since 2017 and developed and directs Bay Psychiatric Associates’ Berkeley Ketamine Clinic, overseeing 10 physicians, seven staff, and approximately 17,000 ketamine and TMS encounters annually.

Her training includes the CIIS Certificate in Psychedelic-Assisted Therapies and Research, MAPS training in MDMA-assisted therapy, and advanced training and clinical research in 5-MeO-DMT.

Dr Sylvestre Quevedo

Amy Emerson

Chief Policy & Strategy Officer, Open Mind Collective • Founder, Emergent Mind

Amy Emerson has spent her career moving treatments from research toward approval. After eleven years in clinical development at Chiron and Novartis, she led MAPS’s MDMA-assisted therapy program for PTSD, co-founded its public benefit corporation, and as CEO of what became Lykos oversaw Phase 3 trials and the first New Drug Application for a psychedelic-assisted therapy.

READ MORE

She planned for what approval alone would not deliver: therapist training, clinic infrastructure, reimbursement, and state policy. She now works with the Office of Systems Catalyst to prepare health systems for approved psychedelic therapies, and serves on Resilient Pharmaceuticals’ board, advising on MDMA resubmission.

Alia Lilienstein, MD, MPH

Alia Lilienstein MD MPH

Director of Clinical Research, Open Mind Collective • UC Berkeley Center for the Science of Psychedelics

Dr. Lilienstein is a board-certified Family Medicine physician with over a decade of experience in psychedelic research. She is a Research Physician at UC Berkeley Center for the Science of Psychedelics, providing medical, regulatory, and operational oversight of psychedelic human studies and conducting study visits, including dosing sessions.

READ MORE

She spent eight years at Lykos Therapeutics as clinical lead for the Phase 3 trials and 2024 FDA New Drug Application for MDMA-assisted therapy for PTSD. She holds an MPH from UC Berkeley, MD from Mount Sinai, residency at Cambridge Health Alliance, and a certificate in Psychedelic-Assisted Therapy and Research from CIIS.

Nicky Mehtani, MD, MPH

Nicky Mehtani MD MPH

Strategic Partnership Lead with UCSF/ZSFG

Nicky Mehtani, MD, MPH, is an addiction medicine physician and Assistant Professor at UCSF, based at Zuckerberg San Francisco General Hospital (ZSFG). Her work focuses on translating promising therapies into real-world care for medically and socially complex populations often underrepresented in clinical trials.

READ MORE

She led the KARE trial of ketamine-assisted therapy for publicly insured patients with methamphetamine use disorder and now leads PRISM, a NIDA-funded trial of psilocybin-assisted therapy for methamphetamine use disorder among people with HIV and the first Schedule I psychedelic trial based at ZSFG. She also serves as a UCSF site co-PI on multisite psychedelic therapy trials.

As a practicing addiction medicine and HIV physician with the San Francisco Department of Public Health, she pioneered a low-barrier program delivering long-acting injectable HIV treatment and prevention to people experiencing homelessness and people who use drugs, populations largely excluded from the pivotal trials that led to these therapies’ FDA approval. The program’s findings, published in JAMA Network Open, show HIV viral suppression rising from roughly one in four patients to 100% over the program’s first four years, demonstrating how implementation research can close the gap between trial efficacy and equitable real-world access.

Andrea Venezia

Andrea Venezia PhD

Strategic Partnership Lead with BCSP

Andrea Venezia brings over 25 years of equity-focused research and policy experience to her role as executive director at the UC Berkeley Center for the Science of Psychedelics (BCSP). Prior to joining the BCSP, she was professor of Public Policy and Administration, and led the Education Insights Center, at California State University (CSU), Sacramento.

READ MORE

Andrea is integrating equity-driven leadership across BCSP’s work, fostering inclusive partnerships, solidifying the BCSP’s vision and values, and strengthening community connections. She is also committed to bridging the gap between psychedelic research and society, ensuring the center’s work has meaningful impact.

Andrea’s scholarship focused on equitable access to and through postsecondary education, encompassing reforms at the high school, community college, and university levels. She co-led the conceptualization and development of the California Education Policy Fellowship Program and the CSU Student Success Network and has authored and coauthored numerous publications, including Supporting the College Dream (2015) by Corwin Press and From High School to College (2004) by Jossey-Bass.

S. Brock Blomberg, PhD, President, California Institute of Integral Studies

S. Brock Blomberg, PhD

President, California Institute of Integral Studies

S. Brock Blomberg is the eighth President of the California Institute of Integral Studies (CIIS), a pioneer in consciousness studies and psychology for more than 50 years and a leader in psychedelic education.

READ MORE

Under his leadership, CIIS launched the nation’s first Bachelor of Science in Psychedelic Studies and opened the nation’s first university-affiliated ketamine-assisted psychotherapy clinic. Both build on a training center that has prepared more than 1,000 mental health professionals. He also commissioned an independent assessment of CIIS’s psychedelic programs to strengthen ethical and professional standards in the field.

His strategic plan, Building On Commitment: CIIS @ 60, makes community wellness a core institutional priority. Before joining CIIS, Dr. Blomberg served as President of Ursinus College, where he led a $107 million campaign, and as Dean of the Robert Day School of Economics and Finance at Claremont McKenna College.

An internationally known political economist, he served as a senior economist for the President’s Council of Economic Advisers and was the U.S. Representative to the Economic Committee for Asia-Pacific Economic Cooperation. He holds a BS in Economics from the University of Tampa and an MA and PhD in Economics from Johns Hopkins University.

Rhonda Reliford, Executive Director of California Institute of Integral Studies

Rhonda Reliford

Executive Director, Office of the President | CIIS

Rhonda Reliford serves as Executive Director of the Office of the President at the California Institute of Integral Studies (CIIS), home of the nation’s first university-based psychedelic therapy training program.

READ MORE

Working closely with university leadership, Rhonda advances institutional strategy, cultivates strategic partnerships, and aligns emerging opportunities with the university’s mission and long-term priorities.

Her work spans institutional governance and cross-sector collaboration. She translates university priorities into actionable initiatives, partnering with faculty, advancement, and external collaborators to move them from concept to implementation. This includes developing the strategy for the next phase of CIIS’s psychedelic education and research and building the partnerships to expand its reach.

She holds an MA in Philosophy and Religion from CIIS’s Philosophy, Cosmology, and Consciousness program, and her scholarship centers on the nature of consciousness and its relationship to contemplative traditions and human experience. In 2025, she presented “Consciousness Unbound” at The Science of Consciousness Conference in Barcelona, Spain.

Rhonda is also the founder of Beyond the Surface, a depth coaching practice that supports self-awareness and personal transformation.

Dr. Janis Phelps

Janis Phelps PhD

Strategic Partnership Lead with CIIS

The Center for Psychedelic Therapy and Research is led by Full Professor Janis Phelps, PhD. Dr. Phelps is a leader in the field of psychedelic therapy training as the Director of the Psychedelic Therapies and Research at the California Institute of Integral Studies Center.

READ MORE

As the Center’s founder, Dr. Phelps developed and launched the first university accredited, post-graduate training program for psychedelic therapy and research. She has held the position of the Dean of Faculty of the six doctoral departments in the CIIS School of Humanities and Social Sciences.

Her 2017 journal publication, Developing Guidelines and Competencies for the Training of Psychedelic Therapists, describes best practices in the academic training of medical and mental health professionals in this field. These ideas are further developed in a 2019 chapter on “Training Psychedelic Therapists” in Advances in Psychedelic Medicine, edited by Michael Winkelman and Ben Sessa.

Dr. Phelps is a board member of the Heffter Research Institute, which has conducted highly influential psilocybin-assisted psychotherapy research since the 1990’s. A licensed clinical psychologist, she is a leader in developing methods of scaling effective training programs to meet the burgeoning need for well-trained mental health and medical professionals in the field of psychedelic medicine.

Dr. Phelps maintains a private clinical practice in Mill Valley, CA.